Antimicrobial and antiviral effects of human defensins: pathogenetic value and prospective application to medicinal therapy

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Defensins, the cationic antimicrobial peptides (AMPs) of phagocytes and epithelial cells, are the key effector molecules of the innate immune system providing the anti-infective host defense. Besides the antimicrobial action, AMPs exert a broad spectrum of varied effects towards host cells giving a ground for considering these peptides as possible biomodulatory molecules. The review outlines different types of the biological activity of structurally diverse AMPs. AMPs posses the potent antimicrobial, antiviruses and lipopolysaccharide-binding activity; some of them are cytotoxic for tumor and normal human cells in vitro, while others demonstrate the wound healing action. AMPs of the defensin family display the corticostatic activity: they inhibit stimulated by adrenocorticotropic hormone (ACTH) steroidogenesis in adrenal cells in vitro. We also showed that defensins and protegrin 3 abolish ACTH- or stress-induced increase of the corticosterone level in blood of experimental animals. Taken together, the described in the literature and our own data contribute to the idea that AMPs are the multifunctional molecules participating in the interaction between the innate and adaptive immune systems as well as between immune and neuroendocrine systems. It considers structure and mechanism of defensins interaction with lipid membrane and intracellular targets of pathogens. Special attention is paid to modern state and perspectives of defensins practical application and also to approaches that increase efficacy by chemical modification of their structure.

Full Text

Restricted Access

About the authors

Vladimir I Vaschenko

S. M. Kirov Military Medical Academy

Author for correspondence.
Email: vladimir-vaschenko@yandex.ru
Dr. Biol. Sci., Senior Researcher, Lab. of the Blood and Tissues, Scientific Research Center

Vladimir N Vil’yaninov

S. M. Kirov Military Medical Academy

Email: vladimir-vaschenko@yandex.ru
PhD, Head, Research Center of the Blood and Tissues, Scientific Research Center

Petr D Shabanov

S. M. Kirov Military Medical Academy

Email: pdshabanov@mail.ru
Professor, Head, Dept. of Pharmacology.

References

  1. Абатуров А.Е., Герасименко И.Л., Высогина М.Ю. Дефенсины и дефенсин-зависимые заболевания. - Одесса: Изд-во ВМВ, 2011. - 265 с. [Abaturov AE, Gerasimenko IL, Visogina MYu. Dеfensins and defensin-dependent diseases. Odessa: Isdatelstvo VMV; 2011. 265 p. (In Russ).]
  2. Азимова В.Т., Потатуркина-Нестерова Н.И., Нестеров А.С. Эндогенные антимикробные пептиды человека // Вестник Ульяновского у-та. - 2012. - Т. 5. - С. 317-320. [Asimova VT, Potaturkina-Nesterova NI, Nesterov AS. Human endogenous antimicrobial peptides (literature review). Vestnik Ulyanovskogo universiteta. 2012; 5:317-320. (In Russ).]
  3. Алешина Г.М., Шамова О.В., Перекрест С.В., и др. Эндотоксин-нейтрализующее действие антимикробных пептидов // Цитокины и воспаление. - 2013. - Т. 2. - № 1-2. - С. 72-77. [Aleshina GM, Shamova OV, Perekrest SV, et al. Endotoksin-neutralised action antimicrobic peptides. Czitokini i vospalenie. 2013;2(1-2): 72-77. (In Russ).]
  4. Будихина А.С., Пинегин Б.В. Дефенсины - мультифункциональные катионные пептиды человека // Иммунопатология, аллергология, инфектология. - 2008. - Т. 2. - С. 31-40. [Budikhina AS, Pinegin BV. Defensins as multifunctional human cationic peptides. Immunopatologia, allergologia i infektologia. 2008;2:31-40. (In Russ).]
  5. Бухарин О.В., Черепшев В.А., Сулейманов К.Г. Антимикробный белок тромбоцитов: монография / О.В. Бухарин, В.А. Черепшев, К.Г. Сулейманов. - Екатеринбург, 2000. - 200 с. [Bucharin OV, Cherepshev VA, Suleymanov KG. Antibacterial platelet peptid; Ecaterinburg; 2000. 200 p. (In Russ).]
  6. Ващенко В.И., Ващенко Т.Н. Биология и физиология протеина С. Современные представления о механизмах лечебного действия активированного протеина С // Обзоры по клин. фарм. и лекарственной терапии. - 2009. - Т. 7. - № 3. - С. 24-47. [Vaschenko VI, Vaschenko TN. Biology and physiology of protein C. Modern of representation about mechanisms of medical action of the activated protein C. Obzori po klin. pharm i lekarstwennoj terapii. 2009;7(3):24-47. (In Russ).]
  7. Ващенко В.И., Хансон К.П., Шабанов П.Д. Цитохром С и лекарственная терапия: прошлое, настоящее, будущее // Обзоры по клин. фарм. и лекарственной терапии. - 2005. - Т. 4. - № 1. - С. 30-41. [Vaschenko VI, Hanson KP, Shabanov PD. Cytochrome C and medicinal therapy: the past, present, future. Obzori po klin. pharm i lekarstwennoj terapii. 2005;4(1):30-41. (In Russ).]
  8. Вильянинов В.Н., Бельгесов Н.В., Калеко С.П., и др. Способ отбора доноров для получения плазмы крови, эффективной при лечении пациентов с инфекционными заболеваниями и осложнениями после оперативных вмешательств, травм и ожогов. Патент на изобретение RUS2558114 от 30. 06. 2015. [Vilyaninov VN, Belgesov NV, Kaleko SP, et al. Way of selection of donors for reception of plasma of blood, effective at treatment of patients with infectious diseases and complications after operative interventions, traumas and burns. Patent RUS2558114 from 30.06.2015. (In Russ).]
  9. Гришин Д.В., Соколов Н.Н. Дефенсины - естественные пептидные антибиотики высших эукариот // Биомедицинская химия. - 2014. - Т. 60. - № 4. - С. 438-447. [Grishin DV, Sokolov NN. Defensins - natural peptide antibiotics of higher eucariotes. Biomedizinskaya chimiya. 2014;4:438-447. (In Russ).]
  10. Ганковская Л.В., Богомильский М.Р., Ганковская О.А., Ланда Р.М. Роль дефенсинов как факторов врожденного иммунитета в защите организма детей с тяжелыми формами паратонзиллитов // Эпидемиология и вакцинопрофилактика. - 2011. - Т. 5. - С. 30-33. [Gankovskya LV, Bogomilskij MR, Gankovskya OA, Landa RM. Role defensins as factors of congenital immunity in protection of an organism of children with heavy forms of a paratonsillitis. Epidemiologia i vakcinoprophilactica. 2011;5:30-33. (In Russ).]
  11. Егоров Ц.А., Одинцова Т.И. Защитные пептиды иммунитета растений (обзорная статья) // Биоорганическая химия. - 2012. - Т. 38. - № 1. - С. 7-17. [Egorov TsA, Odintsova TI. Protective peptides of plant immunity (review). Bioorganicheskaya khimiya. 2012;38(1):7-17. (In Russ).]
  12. Ильяшенко М.Г., Тарасова Г.Н., Гусева А.И. Эндогенные антимикробные пептиды и их клинико-патогенетическая значимость при воспалительных заболеваниях кишечника // Современные проблемы науки и образования. - 2012. - Т. 2. - С. 1-9. [Ilyashenko MG, Tarasova GN, Guseva AI. Human endogenous antimicrobial peptides and their kliniko-pathogenetic importance at inflammatory diseases of intestines. Sovremenie problemi nauki i obrasovaniya. 2012;2:1-9. (In Russ).]
  13. Камышенцев М.В., Шабанов П.Д. Антиреспираторно-вирусные метаболические модуляторы - новый класс средств для терапии и профилактики респираторно-вирусных инфекций // Обзоры по клин. фармакол. и лек. терапии. - 2002. - Т. 1. - № 2. - № 51-63. [Kamishentsev MV, Shabanov PD. Antirespiratorno-virus metabolic modulators - a new class of means for therapy and preventive maintenance of respiratorno-virus infections. Obzori po klin.pharm i lekarstwennoj terapii. 2002;1(2):51-63. (In Russ).]
  14. Кокряков В.Н. Очерки о врожденном иммунитете. - СПб.: Наука, 2006. [Kokryakov VN. Essays on innate immunity. Saint Petersburg: Nauka; 2006 (In Russ).]
  15. Лебедева О.П., Рудых Н.A., Полякова И.С. Антимикробные пептиды - первая линия антиинфекционной защиты женских половых путей // Научные ведомости БелГУ. Сер. Медицина. Фармация. - 2010. - Т. 12. - № 22. - С. 25-30. [Lebedeva OP, Rudih NA, Polyakova IS, Antimicrobial peptides the first line of antiinfectious protection of female sexual ways. Nauchnie vedomoszi BelHu. Seriya Medizina. Pharmaziya. 2010;12(22):25-30. (In Russ).]
  16. Мамчур В.И., Левых А.Э. Дефенсины - эндогенные пептиды с антиинфекционными и противоопухолевыми свойствами // Таврический медико-биологический вестник. - 2012. - Т. 15. - № 2. - С. 315-321. [Mamthur VI, Levih AE. Endogenous antimicrobial peptides with antiinfectious and antineoplastic properties. Tavricheskij medico-biologicheskij vestnic. 2012;2:315-321. (In Russ).]
  17. Манских В.Н. Пути гибели клетки и их биологическое значение // Цитология. - 2007. - Т. 49. - № 11. - С. 909-915. [Manskih VN. Ways of death cells and their biological value. Tzitologiya. 2007;11:909-915. (In Russ).]
  18. Окороченков С.А., Желтухина Г.А., Небольсин В.Е. Антимикробные пептиды: механизмы действия и перспективы практического применения // Биомедицинcкая химия. - 2012. - Т. 58. - № 2. - С. 131-143. [Okorochenkov SA, Sheltuchina GA, Nebolsin VE. Antimicrobial peptides: mechanisms of action and prospect of practical application. Biomedizinskaya chimiya. 2012;58(2):131-143. (In Russ).]
  19. Пруткина Е.В., Сепп А.В., Цыбиков Н.Н. Анализ экспрессии альфа-дефенсинов в легких при респираторном дистресс-синдроме в эксперименте // Фундаментальные исследования. - 2012. - Т. 7. - С. 385-389. [Prutkina EV, Sepp AV, Tsybikov NN. An analysis of alpha-defensins expression in the lungs in a model of respiratory distresssyndrome. Fundamentalnye issledovaniya. 2012;7:385-389. (In Russ).]
  20. Романова Е.Н., Говорин А.В., Горбунов В.В., Лукьянов С.А. Содержание дефенсинов в крови при пневмониях у больных гриппом А/H1N1 // Мед. иммунол. - 2012. - Т. 14. - № 3. - С. 239-242. [Romanova EN, Govorin AV, Gorbunov VV, Luqyanov SA. The maintenance defensins in blood at a pneumonia at sick of ifluenza А/H1N1. Medizinskaya immunologiya. 2012;3:239-242. (In Russ).]
  21. Савельева В.С., Гельфанд Б.Р., ред. Сепсис: классификация, клинико-диагностическая концепция и лечение: практическое руководство. - 2-е изд., доп. и перераб. - М.: ООО «Медицинское информационное агентство», 2010. [Savelyeva VS, Gelfand BR. Sepsis: classification, clinical-diagnostic concept and treatment: a practical guide. Moscow: Meditsinskoe informatsionnoe agentstvo; 2011. (In Russ).]]
  22. Уманский С.Р. Апоптоз: молекулярные и клеточные механизмы // Молекулярная биология. - 1996. - Т. 30. - № 3. - С. 487-502. [Umanskij SR. Аpoptosis: molecular and cellular mechanisms. Moleculjarnaya biologiya. 1996;30(3):487-502. (In Russ).]
  23. Цывкина Е.А., Феденко Е.С., Будихина А.С., Пинегин Б.В. Влияние иммунотропной терапии на уровень α-дефенсинов у больных пиодермией // Российский аллергологический журнал. - 2010. - Т. 6. - С. 22-26. [Tsyvkina EA, Fedenko ES, Pinegin BV. Influence of an immune therapy on alpha-defensin level in peripheral blood in pyodermia patients. Russian alergologicheskij ghurnal. 2010;6;22-26. (In Russ).]
  24. Шамова О.В., Орлов Д.С., Ямщикова Е.В., Орлов С.Б., Кокряков В.Н. Изучение взаимодействия антимикробных пептидов с белками из семейства ингибиторов сериновых протеаз // Фундаментальные исследования. Биологические науки. - 2011. - Т. 9. - С. 344-348. [Shamova OV, Orlov DS, Yamschikova EV, Orlov SB, Kokryakov VN. Investigation of the interaction of antimicrobial peptides with proteins of serine protease inhibitors family. Phundamentalnije issledovanija. Biologicheskie nauki. 2011;9:344-348. (In Russ).]
  25. Шамова О.В., Орлов Д.С., Кокряков В.Н., Корнева Е.А. Антимикробные пептиды в реализации различных защитных функций организма // Медицинский академический журнал. - 2013. - Т. 13. - № 3. - С. 42-52. [Shamova OV, Orlov DS, Kokryakov VN, Korneva EA. Antimicrobial peptides in the realization of varied host defense reaction. Medicinskij academicheskij zhurnal. 2013;3:42-52. (In Russ).]
  26. Aldhous MC, Noble CL, Satsangi J. Dysregulation of human β-defensin-2 protein in inflammatory bowel disease. Public Library of Science Pathogens One. 2009;4:e6285. doi: 10.1371/journal.pone.0006285.
  27. Baillet A, Trocmé C, Berthier S, et al. Synovial fluid proteomic fingerprint: S100A8, S100A9 and S100A12 proteins discriminate rheumatoid arthritis from other inflammatory joint diseases. Rheumatology (Oxford). 2010;49(4):671-682. doi: 10.1093/rheumatology/kep452. Epub 2010 Jan 25.
  28. Baroni A, Donnarumma G, Paoletti I, et al. Structural and functional consequences induced by post-translational modifications in α-defensins. International Journal of Peptides. 2011; Article ID: 594723. doi: 10.1155/2011/594723. Epub 2011 Aug 28.
  29. Bastian J, Valdeyron JL, Vaquier V. [From a relation of confidence to a therapeutic alliance. Conceptual study and its application to nursing care]. Rech Soins Infirm. 2001;66: 93-100. French.
  30. Bechinger B. The structure, dynamics and orientation of antimicrobial peptides in membranes by multidimensional solid-state NMR spectroscopy. Biochim Biophys Acta. 1999;1462(1-2):157-183. doi: 10.1016/S0005-2736(99)00205-9.
  31. Becker S, Quay J, Soukup J. Cytokine (tumor necrosis factor, IL-6, and IL-8) production by respiratory syncytial virus-infected human alveolar macrophages. J Immunol. 1991;147(12):4307-12.
  32. Beisner J, Stange EF, Wehkamp J. Innate antimicrobial immunity in inflammatory bowel diseases. Expert Rev Clin Immunol. 2010; 6(5): 809-918. doi: 10.1586/eci.10.56.
  33. Berlacher MD, Vieth JA, Heflin BC, et al. FcγRIIa ligation induces platelet hypersensitivity to thrombotic stimuli. Am J Pathol. 2013;182(1):244-254. doi: 10.1016/j.ajpath.2012.09.005. Epub 2012 Nov 7.
  34. Bessin Y, Saint N, Marri L, Marchini D, Molle G. Antibacterial activity and pore-forming properties of ceratotoxins: a mechanism of action based on the barrel stave model. Biochim Biophys Acta. Biomembranes. 2004;1667(2):148-156. doi: 10.1016/j.bbamem.2004.09.011.
  35. Biswas A, Liu YJ, Hao L, et al. Induction and rescue of Nod2-dependent Th1- driven granulomatous inflammation of the ileum. Proc Natl Acad Sci USA. 2010;107(33): 14739-14744. doi: 10.1073/pnas.1003363107. Epub 2010 Aug 2.
  36. Bokarewa MI, Jin T, Tarkowski A. Intra articular release and accumulation of defensins and bactericidal/permeability-increasing protein in patients with rheumatoid arthritis. J Rheumatol. 2003;30(8):1719-1724.
  37. Bosire R, John-Stewart GC, Mabuka JM, et al. Breast milk α-defensins are associated with HIV Type 1 RNA and CC chemokines in breast milk but not vertical HIV type 1 transmission. AIDS Res Hum Retroviruses. 2007;23(2):198-203. doi: 10.1089/aid.2006.0125.
  38. Braff MH, Bardan A, Nizet V, Gallo RL. Cutaneous defense mechanisms by antimicrobial peptides. J Invest Dermatol. 2005;125(2):256-263. doi: 10.1111/j.0022-202x.2004.23587.x.
  39. Braff MH, Zaiou M, Fierer J, et al. Keratinocyte production of cathelicidin provides direct activity against bacterial skin pathogens. Infect Immun. 2005;73(10):6771-6781. doi: 10.1128/IAI.73.10.6771-6781.2005.
  40. Brinkmann V, Zychlinsky A. Neutrophil extracellular traps: Is immunity the second function of chromatin? J Cell Biol. 2012;198(5):773-783. doi: 10.1083/jcb.201203170.
  41. Brogden KA. Antimicobial peptides: Pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol. 2005;3: 238-250. doi: 10.1038/nrmicro1098.
  42. Buck CB, Day PM, Thompson CD, et al. Human alpha-defensins block papillomavirus infection. Proc Natl Acad Sci USA. 2006;103(5):1516-1521. doi: 10.1073/pnas.0508033103.
  43. Butmarc J, Yufit T, Carson P, Falanga V. Human beta-defensin-2 expression is increased in chronic wounds. Wound Repair Regen. 2004;12(4):439-443. doi: 10.1111/j.1067-1927.2004.12405.x
  44. Chamaillard M, Dessein R. Defensins couple dysbiosis to primary immunodeficiency in Crohn’s dease. World J of Gastrroeterology. 2011;17(5):567-571. doi: 10.3748/wjg.v17.i5.567.
  45. Chang YY, Ouyang Q. Expression and significance of mucosal beta-defensin-2, TNFalpha and IL-1 beta in ulcerative colitis. Chinese J Internal Med. 2008;47(1):11-14.
  46. Chang TL, Vargas JJr, DelPortillo A, Klotman ME. Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity. J Clin Invest. 2005;115(3):765-773. doi: 10.1172/JCI21948.
  47. Chen C, Yadav PK, Wang X, Liu Z. Regulatory role of defensins in inflammatory bowel disease. Oupen J Immunol. 2012;2(2):78-84. doi: 10.4236/oji2012.22010.
  48. Chen CI, et al. β-defensins and LL-37 in bronchoalveolar lavage fluid of patients with cystic fibrosis. J Cystic Fibrosis. 2004;3:45-50. doi: 10.1016/j.jcf.2003.12.008.
  49. Choi K-Y, Chow LNY, Mookherjee N. Cationic host defence peptides: multifaceted role in immune modulation and inflammation. J Innate Immun. 2012;4:361-370. doi: 10.1159/000336630.
  50. Clark SR, Ma AC, Tavener SA, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med. 2007;13(4):463-469. doi: 10.1038/nm.1565.
  51. Clawson CC, Rao GH, White JG. Platelet interaction with bacteria.IV.Stimulation of the release reaction. Am J Pathol. 1975;81:411-420.
  52. Cohen GM. Caspases: the executioners of apoptosis. Biochem J. 1997;326(Pt1):1-16. doi: 10.1042/bj3260001.
  53. Cohen J. The immunopathogenesis of sepsis. Nature. 2002;420(6917):885-891. doi: 10.1038/nature01326.
  54. Cole AM, Hong T, Boo LM, et al. Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc Natl Acad Sci USA. 2002; 99(4):1813-1818. doi: 10.1073/pnas.052706399.
  55. Currie SM, Findlay EG, McHugh BJ, et al. The human cathelicidin LL-37 has antiviral activity against respiratory syncytial virus. PLoS One. 2013;8(8):e73659. doi: org/10.1371/journal.pone.0073659.
  56. Daher KA, Selsted ME, Lehrer RI. Direct inactivation of viruses by human granulocyte defensins. J Virol. 1986; 60(3):1068-1074.
  57. Dalcin D, Ulanova M. The Role of Human Beta-Defensin-2 in Pseudomonas aeruginosa pulmonary infection in cystic fibrosis patients. Infect Dis Ther. 2013 Dec; 2(2):159-166. doi: 10.1007/s40121-013-0015-5.
  58. Demirkhanyan LH, Marin M, Padilla-Parra S, et al. Multifaceted mechanisms of HIV-1 entry inhibition by human alpha defensin. J Biol Chem. 2012;287(34):28821-28838. doi: 10.1074/jbc.M112.375949. Epub 2012 Jun 25.
  59. Demirkhanyan L, Marin M, Lu W, Melikyan GB. Sub-Inhibitory concentrations of human alpha defensin potentiate neutralizing antibodies against HIV-1 gp41 pre-hairpin intermediates in the presence of serum. PLoS Pathog. 2013;9(6):1-15. doi: 10.1371/journal.ppat.1003431. Epub 2013 Jun 13.
  60. Ding J, Chou YY, Chang, TL. Defensins in viral infections. J Innate Immun. 2009;1(5):413-420. doi: 10.1159/000226256. Epub 2009 Jun 24.
  61. Ding J, Tasker C, Valere K, et al. Anti-HIV activity of human defensin 5 in primary CD4+ T cells under serum-deprived conditions is a consequence of defensin-mediated cytotoxicity. PLoS One. 2013;8(9):1-11. doi: 10.1371/journal.pone.0076038. eCollection 2013.
  62. Dormehl IC, Kilian JG, Maree M, Jacobs L. Investigation by scintigraphic methods of platelet kinetics under normal and septic shock conditions in the experimental baboon model. Am J Physiol Imaging. 1990;5(2):75-79.
  63. Doss M, White MR, Tecle T, Hartshorn KL. Human defensins and LL-37 in mucosal immunity. J Leuk Biology. 2010; 87(1):79-92. doi: 10.1189/jlb.09.0609382.
  64. Dugan AS, Maginnis MS, Jordan JA, et al. Human alpha-defensins inhibit BK virus infection by aggregating virions and blocking binding to host cells. J Biol Chem. 2008; 283(45):31125-31132. doi: 10.1074/jbc.M805902200. Epub 2008 Sep 9.
  65. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495-516. doi: 10.1080/ 01926230701320337.
  66. Fan SR, Liu XP, Liao QP. Human defensins and cytokines in vaginal lavage fluid of women with bacterial vaginosis. Int J Gynaecol Obstet. 2008;103(1):50-54. doi: 10.1016/j.ijgo.2008.05.020. Epub 2008 Jul 16.
  67. Feng Z, Dubyak GR, Lederman MM, Weinberg A. Cutting edge: human beta defensin 3 a novel antagonist of the HIV-1 coreceptor CXCR4. J Immunol. 2006;177(2):782-786. doi: 10.4049/jimmunol.177.2.782.
  68. Findlay EG, McHugh BJ, Mackellar A, Man T. The human cathelicidin LL-37 has antiviral activity against respiratory syncytial virus. PLoS One. 2013;8(8):1-10. doi: 10.1371/journal.pone.0073659. eCollection 2013.
  69. Flatt JW, Kim R, Smith JG, Nemerow GR, Stewart PL. An intrinsically disordered region of the adenovirus capsid is implicated in neutralization by human alpha defensin 5. PLoS One. 2013;8(4):1-10. doi: 10.1371/journal.pone.0061571. Print 2013.
  70. Francois B, Trimoreau F, Vignon P, et al. Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor. Am J Med. 1997; 103(2):114-120. doi: 10.1016/S0002-9343(97)00136-8.
  71. Fritsche TR, Rhomberg PR, Sader HS, Jones RN. Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections. J Antimicrob Chemother. 2008;61(5):1092-1098. doi: 10.1093/jac/dkn074.
  72. Fujii G, Selsted ME, Eisenberg D. Defensins promote fusion and lysis of negatively charged membranes. Protein Sci. 1993;2(8):1301-1312. doi: 10.1002/pro.5560020813.
  73. Funderburg N, Lederman MM, Feng Z, et al. Human-defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2. Proc Natl Acad Sci USA. 2007;104(47): 18631-18635. doi: 10.1073/pnas.0702130104.
  74. Furci L, Sironi F, Tolazzi M, Vassena L, Lusso P. Alpha-defensins block the early steps of HIV-1 infection: interference with the binding of gp120 to CD4. Blood. 2007; 109(7):2928-2935.
  75. Gafter-Gvili A, Mansur N, Bivas A, et al. Thrombocytopenia in Staphylococcus aureus bacteremia: risk factors and prognostic importance. Mayo Clin Proc. 2011;86(5): 389-396. doi: 10.4065/mcp.2010.0705.
  76. Gallo SA, Wang W, Rawat SS, et al. Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation. J Biol Chem. 2006; 281(27):18787-18792. doi: 10.1074/jbc.M602422200.
  77. Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol. 2004;2(1): 33-42. doi: 10.1038/nrmicro794.
  78. Ganz T, Selsted ME, Szklarek D, et al. Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest. 1985;76(4):1427-1435. doi: 10.1172/JCI112120.
  79. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol. 2003;3(9):710-720. doi: 10.1038/nri1180.
  80. Gersemann M, Wehkamp J, Fellermann K, Stange EF. Crohn’s disease-defect in innate defence. World Journal of Gastroenterology. 2008;14(36):5499-5503. doi: 10.3748/wjg.14.5499.
  81. Greer A, Zenobia C, Darveau RP. Defensins and LL-37: A review of function in the gingival epithelium. Periodontol 2000. 2013;63(1):67-79. doi: 10.1111/prd.12028.
  82. Gordon Y, Romanowski E, Mcdermott A. A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs. Curr Eye Res. 2005;30(7):505-515. doi: 10.1080/02713680590968637.
  83. Gounder AP, Wiens ME, Wilson SS, et al. Critical determinants of human alpha-defensin 5 activity against non-enveloped viruses. J Biol Chem. 2012;287(9):24554-24562. doi: 10.1074/jbc.M112.354068. Epub 2012 May 25.
  84. Gregory SM, Nazir ShN, Metcalf JP. Implications of the innate immune response to adenovirus and adenoviral vectors. Future Virol. 2011;6(3):357-374. doi: 10.2217/fvl.11.6.
  85. Grubor B, Gallup JM, Meyerholz DK, et al. Enhanced surfactant protein and defensin mRNA levels and reduced viral replication during parainfluenza virus type 3 pneumonia in neonatal lambs. Clin Diagn Lab Immunol. 2004;11(3):599-607. doi: 10.1128/cdli.11.3.599-607.2004.
  86. Guo CJ, Tan N, Song L, et al. Alpha-defensins inhibit HIV infection of macrophages through upregulation of CC-chemokines. Aids. 2004;18(8):1217-1218. doi: 10.1097/00002030-200405210-00020.
  87. Gutierrez A, Holler E, Zapater P, et al. Antimicrobial peptide response to blood translocation of bacterial DNA in Crohn’s disease is affected by NOD2/CARD15 genotype. Inflammatory Bowel Diseases. 2011;17(8):1641-1650. doi: 10.1002/ibd.21537. Epub 2010 Nov 15.
  88. Hamzeh-Cognasse H, Damien P, et al. Platelet and infection - complex interactions with bacteria. Front Immunol. 2015;6:82. doi:org/10.3389/immu.2015.00082.
  89. Hancock R, Chapple D. Peptide antibiotics. Antimicrob Agents Chemother. 1999;43(6):1317-1323.
  90. Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol. 2006;24(12):1551-1567. doi: 10.1038/nbt1267.
  91. Harder J, Meyer-Hoffert U, Teran LM, at al. Mucoid Pseudomonas aeruginosa, TNF-alpha, and IL-1beta, but not IL-6, induce human beta-defensin-2 in respiratory epithelia. Am J Respir Cell Mol Biol. 2000;22(6):714-21. doi: 10.1165/ajrcmb.22.6.4023.
  92. Harrison SC. Viral membrane fusion. Nat Struct Mol Biol. 2008;15(7):690-698. doi: 10.1038/nsmb.1456.
  93. Hartshorn KL, White MR, Tecle T, et al. Innate defense against influenza A virus: activity of human neutrophil defensins and interactions of defensins with surfactant protein D. J Immunol. 2006;176(11):6962-6972. doi: 10.4049/jimmunol.176.11.6962.
  94. Hazlett L, Wu M. Defensins in innate immunity. Cell Tissue Res. 2011;343(1):175-178. doi: 10.1007/s00441-010-1022-4. Epub 2010 Aug 21.
  95. Hazrati E, Galen B, Lu W, et al. Human alpha- and beta-defensins block multiple steps in herpes simplex virus infection. J Immunol. 2006;177(12):8658-8666. doi: 10.4049/jimmunol.177.12.8658.
  96. Hendrickx K, Stichling N, Koelen J, et al. Innate immunity to adenovirus. Human Gene Therapy. 2014;25:265-284. doi: 10.1089/hum.2014.001.
  97. Higazi AA, Ganz T, Kariko K, Cines DB. Defensin modulates tissue-type plasminogen activator and plasminogen binding to fibrin and endothelial cells. J Biol Chem. 1996;271(30):17650-5. doi: 10.1074/jbc.271.30.17650.
  98. Hirsch T, Spielmann M, Zuhaili B, et al. Human beta-defensin-3 promotes wound healing in infected diabetic wounds. J Genet Med. 2009;11(3):220-228. doi: 10.1002/jgm.1287.
  99. Howell MD, Streib JE, Leung DY. Antiviral activity of human beta-defensin 3 against vaccinia virus. J Allergy Clin Immunol. 2007;119(4):1022-1025. doi: 10.1016/j.jaci.2007.01.044.
  100. Huang HW. Action of antimicrobial peptides:two-state model. Biochemistry. 2000;39(8):8347-8352. doi: 10.1021/bi000946l
  101. Jensen H, Hawill P, Hancook RE. Peptide antimicrobial agents. Clin Microbiol Rev. 2006;19(3):491-511. doi: 10.1128/CMR.00056-05.
  102. Josefsson EC, White MJ, Dowling MR, Kile BT. Platelet life span and apoptosis. Methods Mol Biol. 2012;788:59-71. doi: 10.1007/978-1-61779-307-3_5.
  103. Inaba Y, Ashida T, Ito T, et al. Expression of the antimicrobial peptide alpha-defensin/cryptdins in intestinal crypts decreases at the initial phase of intestinal inflammation in a model of inflammatory bowel disease, IL-10-deficient mice. Inflammatory Bowel Diseases. 2010;16(9):1488-1495. doi: 10.1002/ibd.21253.
  104. Pak V, Budikhina A, Pashenkov M, Pinegin B. Neutrophil activity in chronic granulomatous disease. Adv Exp Med Biol. 2007;601:69-74. doi: 10.1007/978-0-387-72005-0_7.
  105. Kaus A, Jacobsen F, Sorkin M, et al. Host defense peptides in human burns. Burns. 2008;34(17):1381-90.
  106. Kim JM. Antimicrobial proteins in intestine and inflammatory bowel disease. Intest Res. 2014;12(1):20-33. doi: 10.5217/ir.2014.12.1.20. Epub 2014 Jan 28.
  107. Kisich KO, Howell MD, Boguniewicz M, et al. The constitutive capacity of human keratinocytes to kill Staphylococcus aureus is dependent on beta-defensin 3. J Invest Dermatol. 2007;10:2368-2380. doi: 10.1038/sj.jid.5700861.
  108. Klasse PJ. The molecular basis of HIV entry. Cellular Microbiology. 2012;14(8):1183-1192. doi: 10.1111/j.1462-5822.2012.01812.x. Epub 2012 Jun 5.
  109. Klotman ME, Rapista A, Teleshova N, et al. Neisseria gonorrhoeae-induced human defensins 5 and 6 increase HIV infectivity: role in enhanced transmission. J Immunol. 2008;180(9):6176-6185. doi: 10.4049/jimmunol.180.9.6176.
  110. Kocsis AK, Lakatos PL, Somogyvari F, et al. Association of beta-defensin 1 single nucleotide polymerphisms with Crohn’s disease. Gastroenterology. 2008;43(3):299-307.
  111. Koo SP, Bayer A, Yeaman M. Diversity in antistaphylococcal mechanisms among membrane-targeting antimicrobial peptides. Infect Immun. 2001;69(8):4916-4922. doi: 10.1128/IAI.69.8.4916-4922.2001.
  112. Kota S, Sabbah A, Chang TH, et al. Role of human beta-defensin-2 during tumor necrosis factor-alpha/NF-kappaB-mediated innate antiviral response against human respiratory syncytial virus. J Biol Chem. 2008;283(33):22417-22429. doi: 10.1074/jbc.M710415200. Epub 2008 Jun 20.
  113. Kraemer BF, Campbell RA, Schwertz H, et al. Novel anti-bacterial activities of β-defensin 1 in human platelets: suppression of pathogen growth and signaling of Neutrophil Extracellular Trap Formation. PLoS Pathog. 2011;7(11):1002355. doi: 10.1371/journal.ppat.1002355. Epub 2011 Nov 10.
  114. Kraemer BF, Campbell RA, Schwertz H, et al. Bacteria differentially induce degradation of Bcl-xL, asur-vival protein, by human platelets. Blood. 2012;120(25):5014-5020. doi: 10.1182/blood-2012-04-420661. Epub 2012 Oct 18.
  115. Kral JB, Schrottmaier WC, Salzmann M, Assinger A. Platelet interaction with innate immune cells.Transfus Med Hemother. 2016;43:78-88. doi: 10.1159/000444807.
  116. Kuhn L, Trabattoni D, Kankasa C, et al. Alpha-defensins in the prevention of HIV transmission among breastfed infants. J Acquir Immune Defic Syndr. 2005;39:138-142.
  117. Lafferty MK, Sun L, DeMasi L, et al. CCR6 ligands inhibit HIV by inducing APOBEC3G. Blood. 2010;115(8):1564-71. doi: 10.1182/blood-2009-06-226423. Epub 2009 Dec 18.
  118. Lehrer RI. Primate defensins. Nat Rev Microbiol. 2004;2(9):727-738. doi: 10.1038/nrmicro976.
  119. Lehrer RI, Jung G, Ruchala P, et al. Multivalent binding of carbohydrates by the human alpha-defensin, HD5. J Immunol. 2009;183(1):480-490. doi: 10.4049/jimmunol.0900244.
  120. Leikina E, Delanoe-Ayari H, Melikov K, et al. Carbohydrate-binding molecules inhibit viral fusion and entry by crosslinking membrane glycoproteins. Nat Immunol. 2005;6(10):995-1001. doi: 10.1038/ni1248.
  121. Leytin V. Apoptosis in the anucleate platelet. Blood Rev. 2012;26(2):51-63. doi: 10.1016/j.blre.2011.10.002. Epub 2011 Nov 4.
  122. Leytin V, Allen DJ, Mykhaylov S, et al. Thrombin-triggered platelet apoptosis. J Thromb Haemost. 2006;4(12):2656-2663. doi: 10.1111/j.1538-7836.2006.02200.x.
  123. Levinson P, Kaul R, Kimani J, et al. Levels of innate immune factors in genital fluids: association of alpha defensins and LL-37 with genital infections and increased HIV acquisition. AIDS. 2009;23(3):309-317. doi: 10.1097/QAD.0b013e328321809c.
  124. Li J, Xia Y, Bertino AM, et al. The mechanism of apoptosis in human platelets during storage. Transfusion. 2000;40(11):1320-1329. doi: 10.1046/j.1537-2995. 2000.40111320.x.
  125. Liao Z, Dong J, Hu X, et al. Enhanced expression of human β-defensin 2 in peripheral lungs of patients with chronic obstructive pulmonary disease. Peptides. 2012;38(2):350-356. doi: 10.1016/j.peptides.2012.09.013. Epub 2012 Sep 19.
  126. Lombardo B, Feghali K, Zhao L, et al. Green tea extract and its major constituent, epigallocatechin-3-gallate, induce epithelial beta-defensin secretion and prevent beta-defensin degradation by Porphyromonas gingivalis. J Periodontal Res. 2014;49(5):615-23. doi: 10.1111/jre.12142. Epub 2013 Nov 9.
  127. Lu W, de Leeuw E. Proinflammatory and proapoptotic properties of human defensin 5. Biochem Biophys Res Commun. 2013;436(3):557-562. doi: 10.1016/j.bbrc.2013.06.015. Epub 2013 Jun 11.
  128. Ma AC, Kubes P. Platelets, neutrophils, and neutrophil extracellular traps (NETs) in sepsis. J Thromb Haemost. 2008;6(3):415-20. doi: 10.1111/j.1538-7836.2007.02865.x.
  129. Mackewicz CE, Yuan J, Tran P, et al. Alpha-defensins can have anti-HIV activity but are not CD8 cell anti-HIV factors. Aids. 2003;17(14):F23-F32. doi: 10.1097/00002030-200309260-00001.
  130. Mani R, Cady S, Tang M, et al. Membrane-dependent oligomeric structure and pore formation of a beta-hairpin antimicrobial peptide in lipid bilayers from solid-state NMR. Proc Natl Acad Sci USA. 2006;103(44):16242-16247. doi: 10.1073/pnas.0605079103.
  131. Matsuzaki K, Murase O, Fujii N, Miyajima K. An antimicrobial peptide, magainin 2, induced rapid flip-flop of phospholipids coupled with pore formation and peptide translocation. Biochemistry. 1996;35(35):11361-11368. doi: 10.1021/bi960016v.
  132. Matsuzaki K, Sugishita K, Harada M, et al. Interactions of an antimicrobial peptide, magainin 2, with outer and inner membranes of Gram-negative bacteria. Biochim Biophys Acta. 1997;1327(1):119-130. doi: 10.1016/S0005-2736(97)00051-5.
  133. Mayr FB, Yende S, Angus DC. Epidemiology of severe Sepsis. Virulence. 2014;5(1):4-11. doi: 10.4161/viru.27372. Epub 2013 Dec 11.
  134. Meyerholz DK, Grubor B, Gallup JM, et al. Adenovirus-mediated gene therapy enhances parainfluenza virus 3 infection in neonatal lambs. J Clin Microbiol. 2004;42:4780-4787. doi: 10.1128/JCM.42.10.4780-4787.2004.
  135. Menzies BE, Kenoyer A. Signal transduction and nuclear responses in staphylococcus aureus-induced expression of human beta-defensin-3 in skin keratinocytes. Infect Immun. 2006;74(12):6847-6854. doi: 10.1128/IAI.00389-06.
  136. Mercer J, Schelhaas M, Helenius A. Virus entry by endocytosis. Annu Rev Biochem. 2010;79:803-833. doi: 10.1146/annurev-biochem-060208-104626.
  137. Moris MC, Depollier J, Mery J, et al. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol. 2001;19(12):1173-6. doi: 10.1038/nbt1201-1173.
  138. Moyer CL, Wiethoff CM, Maier O, et al. Functional genetic and biophysical analyses of membrane disruption by human adenovirus. J Virol. 2011;85(6):2631-2641. doi: 10.1128/JVI.02321-10. Epub 2011 Jan 5.
  139. Mudter J. What’s new about inflammatory bowel diseases in 2011. World J of Gastroenterology. 2011;17(27):3177. doi: 10.3748/wjg.v17.i27.3177.
  140. Mukae H, Iiboshi H, Nakazato M, et al. Raised plasma concentrations of α-defensins in patients with idiopathic pulmonary fibrosis. Thorax. 2002;57(7):623-628. doi: 10.1136/thorax.57.7.623.
  141. Munk C, Wei G, Yang OO, et al. The theta-defensin, retrocyclin, inhibits HIV-1 entry. AIDS Res Hum Retroviruses. 2003;19(10):875-881. doi: 10.1089/08892220332249 3049.
  142. Nagata S. Apoptosis by death factor. Cell. 1997;88(3):355-365. doi: 10.1016/S0092-8674(00)81874-7.
  143. Nguyen EK, Nemerow GR, Smith JG. Direct evidence from single-cell analysis that human alphadefensins block adenovirus uncoating to neutralize infection. J Virol. 2010;84(8):4041-4049. doi: 10.1128/JVI.02471-09. Epub 2010 Feb 3.
  144. Nguyen KA, Hamzeh-Cognasse H, Palle S, et al. Role of siglec-7 in apoptosis in human platelets. PloS One. 2014;9(9):1-12. doi: 10.1371/journal.pone.0106239. eCollection 2014.
  145. Ngyuen TX, Cole AM, Lehrer RI. Evolution of primate theta-defensins:a serpentine path to a sweet tooth. Peptides. 2003;24(11):1647-54. doi: 10.1016/j.peptides.2003.07.023.
  146. Oono T, Shirafuji Y, Huh WK, et al. Effects of human neutrophil peptide-1 on the expression of interstitial collagenase and type I collagen in human dermal fibroblasts. Arch Dermatol Res. 2002;294(4):185-189. doi: 10.1007/s00403-002-0310-6.
  147. Ou G, Baranov V, Lundmark E, Hammarström S, Hammarström ML. Contribution of intestinal epithelial cells to innate immunity of the human gut-Studies on polarized monolayers of colon carcinoma cells. Scandinavian J of Immunology. 2009;69(2):150-161. doi: 10.1111/j.1365-3083.2008.02208.x.
  148. Oulette AJ. Paneth cell alpha-defensin synthesis and function. Curr Top Microbiol Immunol. 2006;306:1-25. doi: 10.1007/3-540-29916-5_1.
  149. Ovchinnikova T, Shenkarev Z, Balandin S, et al. Molecular insight into mechanism of antimicrobial action of the beta-hairpin peptide arenicin:specific oligomerization in detergent micelles. Biopolymers. 2008;89(5):455-464. doi: 10.1002/bip.20865.
  150. Pace E, Giarratano A, Ferraro M, et al. TLR4 upregulation underpins airway neutrophilia in smokers with chronic obstructive pulmonary disease and acute respiratory failure. Hum Immunol. 2011;72(1):54-62. doi: 10.1016/j.humimm.2010.09.009. Epub 2010 Oct 1.
  151. Panyutich A, Hiemstra P, van Wetering S, Ganz T. Human neutrophil defensins and serpins form complexes and inactivate each other. Am J of Respiratory Cell Molecular Biology. 1995;12:351-357. doi: 10.1165/ajrcmb.12.3.7873202.
  152. Paulsen F, Pufe T, Conradi L, et al. Antimicrobial peptides are expressed and produced in healthy and inflamed human synovial membrane. J Pathol. 2002;198(3):369-377. doi: 10.1002/path.1224.
  153. Paulsen F, Pufe T, Petersen W, Tillmann B. Expression of natural peptide antibiotics in human articular cartilage and synovial membrane. Clin Diag Lab Immunol. 2001;8(5):1021-1023. doi: 10.1128/cdli.8.5.1021-1023.2001.
  154. Pazgier M, Li X, Lu W, Lubkowski J. Human defensins: synthesis and structural properties. Curr Pharm Des. 2007;13(30):3096-3118. doi: 10.2174/138161207782110381.
  155. Pazgier M, Wei G, Ericksen B, et al. Sometimes it takes two to tango:contributions of dimerization to functions of human alpha-defensin HNP1 peptide. J Biol Chem. 2012;287(12):8944-53. doi: 10.1074/jbc.M111.332205. Epub 2012 Jan 23.
  156. Peerschke EI, Yin W, Ghebrehiwet B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol. 2010;47(13):2170-2175. doi: 10.1016/j.molimm.2010.05.009. Epub 2010 Jun 1.
  157. Perez-Berna AJ, Ortega-Esteban A, Menendez-Conejero R, et al. The role of capsid maturation on adenovirus priming for sequential uncoating. J Biol Chem. 2012;287(37):31582-31595. doi: 10.1074/jbc.M112.389957. Epub 2012 Jul 12.
  158. Pereira AL, Franco GC, Cortelli SC, et al. Influence of periodontal status and periodontopathogens on levels of oral human β-defensin-2 in saliva. J Periodontol. 2013;84(10):1445-53. doi: 10.1902/jop.2012.120321. Epub 2012 Nov 23.
  159. Perl M, Chung C-Sh, Swan R, Ayala A. Role of programmed cell death in the immunopathogenesis of sepsis. Drug Discov Today Dis Mech. 2007;4(4):223-230. doi: 10.1016/j.ddmec.2008.02.010.
  160. Peyrin-Biroulet L, Vignal C, Dessein R, et al. NODs in defence: From vulnerable antimicrobial peptides to chronic inflammation. Trends in Microbiology. 2009;14(10):432-438. doi: 10.1016/j.tim.2006.08.008.
  161. Philipson M, Kubes P, Swan R, Ayala A. Role of programmed cell death in the immunopathogenesis of sepsis. Drug Discov Today Dis Mech. 2011;4(4):223-230.
  162. Poindexter BJ, Bhat S, Buja LM, et al. Localization of antimicrobial peptides in normal and burned skin. Burns. 2006;32(4):402-407. doi: 10.1016/j.burns.2006.01.021.
  163. Pouny Y, Rapaport D, Mor A, et al. Interaction of antimicrobial dermaseptin and its fluorescently labeled analogues with phospholipid membranes. Biochemistry. 1992;31(49):12416-23. doi: 10.1021/bi00164a017.
  164. Powers JP, Hancock R. The relationship between peptide structure and antibacterial activity. Peptides. 2003;24(24):1681-1691. doi: 10.1016/j.peptides.2003. 08.023.
  165. Qiu HN, Wong CK, Chu MT, et al. Muramyl dipeptide mediated activation of human bronchial epithelial cells interacting with basophils:a novel mechanism of airway inflammation. Clin Exp Immunol. 2013;172(1):81-94. doi: 10.1111/cei.12031.
  166. Quinones-Mateu ME, Lederman MM, Feng Z, et al. Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. Aids. 2003;17(16):F39-48. doi: 10.1097/00002030-200311070-00001.
  167. Rahman A, Fahlgren A, Sitohy B, et al. Beta-defensin production by human colonic plasma cells: A new look at plasma cells in ulcerative colitis. Inflammatory Bowel Diseases. 2007;13(7):847-855. doi: 10.1002/ibd.20141.
  168. Rapista A, Ding J, Benito B, et al. Human defensins 5 and 6 enhance HIV-1 infectivity through promoting HIV attachment. Retrovirology. 2011;8(45):1-10. doi: 10.1186/1742-4690-8-45.
  169. Ricci E, Malacrida S, Zanchetta M, et al. Role of betadefensin-1 polymorphisms in mother-tochild transmission of human immunodeficiency virus type 1. J Acquir Immune Defic Syndr. 2009;51(1):13-19. doi: 10.1097/QAI.0b013e31819df249.
  170. Riepl B, Grässel S, Wiest R, et al. Tumor necrosis factor and norepinephrine lower the levels of human neutrophil peptides 1-3 secretion by mixed synovial tissue cultures in osteoarthritis and rheumatois arthritis. Arthrit Res Ther. 2010;12(3):R110. doi: 10.1186/ar3044. Epub 2010 Jun 4.
  171. Robinson K, Deng Z, Hou Y, Zhang, G. Regulation of the intestinal barrier function by host defense peptides. Front Veter Science. 2015;2(Article57):1-17. doi: 10.3389/fvets.2015.00057. eCollection 2015.
  172. Salzman NH, Underwood MA, Bevins CL. Paneth cells, defensins, inhibits and the commensal microbiota: a hipothesis on intimate interplay at the intestinal mucosa. Seminars Immunol. 2007;19(2):70-83. doi: 10.1016/j.smim.2007.04.002.
  173. Sang Y, Ruchala P, Lehrer RI, et al. Antimicrobial host defense peptides in an arteriviral infection: differential peptide expression and virus inactivation. Viral Immunol. 2009;22:235-242. doi: 10.1089/vim.2009.0005.
  174. Sato T, van Es JH, Snippert HJ. Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature. 2011;469(7330):415-418. doi: 10.1038/nature09637. Epub 2010 Nov 28.
  175. Schneider JJ, Unholzer A, Schaller M, et al. Human defensins. J Mol Med. (Berl.). 2005;83(8):587-595. doi: 10.1007/s00109-005-0657-1.
  176. Schroeder JM, Harder J. Human beta-defensing-2. Int J Biochem Cell Biol. 1999;31(6):645-651. doi: 10.1016/S1357-2725(99)00013-8.
  177. Schroeder JM, Harder J. Inducible and constitutive beta-defensins are differentially expressed in Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis. 2006. 2003;9(4):215-23.
  178. Secor D, Li F, Ellis CG, et al. Impaired microvascular perfusion in sepsis requires activated coagulation and P-selectin-mediated platelet adhesion in capillaries. Intensive Care Med. 2010;36(11):1928-1934. doi: 10.1007/s00134-010-1969-3. Epub 2010 Aug 6.
  179. Seidel A, Ye Y, De Armas LR, et al. Cyclic and acyclic defensins inhibit human immunodeficiency virus type-1 replication by different mechanisms. PLoS One. 2010;5(3):e9737. doi: 10.1371/journal.pone.0009737.
  180. Selsted ME, Ouellette AJ. Mammalian defensins in the antimicrobial immune response. Nat Immunol. 2005;6(6):551-557. doi: 10.1038/ni1206.
  181. Selsted ME. Theta-defensins: cyclic antimicrobial peptides produced by binary ligation of truncated alpha-defensins. Curr Protein Pept Sci. 2004;5:365-371. doi: 10.2174/1389203043379459.
  182. Sengupta D, Hari L, Mark A, Marrink SJ. Toroidal pores formed by antimicrobial peptides show significant disorder. Biochim Biophys Acta - Biomembranes. 2008;1778(10):2308-2317. doi: 10.1016/j.bbamem.2008.06.007. Epub 2008 Jun 18.
  183. Semeraro F, Ammollo CT, Morrissey JH, et al. Extracellular histones promote thrombin generation through platelet-dependent mechanisms:involvement of platelet TLR2 and TLR4. Blood. 2011;118(7):1952-1961. doi: 10.1182/blood-2011-03-343061. Epub 2011 Jun 14.
  184. Semple F, Webb S, Li HN, et al. Human beta-defensin 3 has immunosuppressive activity in vitro and in vivo. Eur J Immunol. 2010;40(4):1073-1078. doi: 10.1002/eji.200940041.
  185. Shai Y, Oren Z. Selective lysis of bacteria but not mammalian cells by diastereomers of melittin: structure-function study. Biochemistry. 1997;36(7):1826-35. doi: 10.1021/bi962507l.
  186. Shai Y. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim Biophys Acta. 1999;1462(1-2):55-70. doi: 10.1016/S0005-2736(99)00200-X.
  187. Sieczkarski SB, Brown HA, Whittaker, GR. Role of protein kinase C betaII in influenza virus entry via late endosomes. J Virol. 2003;77(1):460-9. doi: 10.1128/JVI.77.1.460-469.2003.
  188. Silva A. Jr, Teschke O. Effects of the antimicrobial peptide PGLa on live Escherichia coli. Biochim Biophys Acta. 2003;1643(1-3):95-103. doi: 10.1016/j.bbamcr.2003.10.001.
  189. Simms LA, Doecke JD, Walsh MD, et al. Reduced α-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn’s disease. Gut. 2008;57:903-910. doi: 10.1136/gut.2007.142588.
  190. Smith JB, Haynes MK. Rheumatoid arthritis - a molecular understanding. Ann Intern Med. 2002;136(12):908-922. doi: 10.7326/0003-4819-136-12-200206180-00012.
  191. Smith JG, Nemerow GR. Mechanism of adenovirus neutralization by human alpha-defensins. Cell Host Microbe. 2008;3(1):11-19. doi: 10.1016/j.chom.2007.12.001.
  192. Smith J.G, Silvestry M, Lindert S, et al. Insight into the mechanisms of adenovirus capsid disassembly from studies of defensin neutralization. PLoS Pathog. 2010;6(6):1-11. doi: 10.1371/journal.ppat.1000959.
  193. Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370(9602):1861-1874.
  194. Snijder J, Reddy VS, May ER, et al. Integrin and defensing modulate the mechanical properties of adenovirus. J Virol. 2013;87(5):2756-2766. doi: 10.1128/JVI.02516-12. Epub 2012 Dec 26.
  195. Sorensen O.E, Cowland J.B, Theilgaard-Monch K, et al. Wound healing and expression of antimicrobial peptides/polypeptides in human keratinocytes, a consequence of common growth factors. J Immunol. 2003;170(11):5583-5589. doi: 10.4049/jimmunol.170.11.5583.
  196. Sorensen OE, Thapa DR, Rosenthal A, et al. Differential regulation of beta-defensin expression in human skin by microbial stimuli. J Immunol. 2005;174(8):4870-4879. doi.org/10.4049/jimmunol.174.8.4870
  197. Steinstraesser L, Ring A, Bals R, et al. The human host defense peptide LL37/hCAP accelerates angiogenesis in PEGT/PBT biopolymers. Ann Plast Surg. 2006;56(1):93-98. doi: 10.1097/01.sap.0000190883.30005.91.
  198. Steven WK. Dermot Cox Platelet-bacterial interactions. Cell Mol Life Sciences. 2010;67(4):513-523. doi: 10.1007/s00018-009-0207-z. Epub 2009 Nov 29.
  199. Takeuchi K, Takahashi H, Sugai M, et al. Channel-forming membrane permeabilization by an antibacterial protein, sapecin:determination of membrane-buried and oligomerization surfaces by NMR. J Biol Chem. 2004;279(6):4981-4987. doi: 10.1074/jbc.M307815200.
  200. Sun L, Finnegan C.M, Kish-Catalone T, et al. Human beta-defensins suppress human immunodeficiency virus infection:potential role in mucosal protection. J Virol. 2005;79:14318-14329. doi: 10.1128/JVI.79.22.14318-14329.2005.
  201. Supp DM, Karpinski AC, Boyce ST. Expression of human beta-defensins HBD-1, HBD-2, and HBD-3 in cultured keratinocytes and skin substitutes. Burns. 2004;30(7):643-648. doi: 10.1016/j.burns.2004.03.012.
  202. Tecle T, White MR, Gantz D, Crouch EC, Hartshorn KL. Human neutrophil defensins increase neutrophil uptake of influenza A virus and bacteria and modify virus-induced respiratory burst responses. J Immunol. 2007;178(12):8046-8052. doi: 10.4049/jimmunol.178.12.8046.
  203. Trabattoni D, Caputo SL, Maffeis G, et al. Human alpha defensin in HIV-exposed but unifected individuals. J Acquir Immune Defic Syndr. 2004;35(0):455-463. doi: 10.1097/00126334-200404150-00003.
  204. Toke O. Antimicrobial peptides: new candidates in the fight against bacterial infections. Biopolymers. 2005;80(6):717-735. doi: 10.1002/bip.20286.
  205. Tympl K. Critical role for oxidative stress, platelets, and coagulation in capillary blood flow impairment in sepsis. Microcirculation. 2011;18(2):152-162. doi: 10.1111/j.1549-8719.2010.00080.x.
  206. Yadav PK, Chen C, Liu, Z. Potential role of NK cells in the pathogenesis of inflammatory bowel disease. J of Biomedicine Biotechnology. 2011;Article ID:1-6. doi: 10.1155/2011/348530. Epub 2011 Jun 1.
  207. Yamakawa K, Ogura H, Koh T, et al. Platelet mitochondrial membrane potential correlates with severity in patients with systemic inflammatory response syndrome. J Trauma Acute Care Surg. 2013;74(2):411-417. doi: 10.1097/TA.0b013e31827a34cf.
  208. Yamaguchi N, Isomoto H, Mukae H, et al. Concentrations of alpha- and beta-defensins in plasma of patients with inflammatory bowel disease. Inflammation Research. 2009;58(4):192-197. doi: 10.1007/s00011-008-8120-8.
  209. Yasin B, Wang W, Pang M, et al. Theta defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry. J Virol. 2004;78(10):5147-5156. doi: 10.1128/JVI.78.10.5147-5156.2004.
  210. Yipp BG, Kubes P. NETosis: vital is it? Blood. 2013;122(16):2784-94. doi: 10.1182/blood-2013- 04-457671. Epub 2013 Sep 5.
  211. Yousefi S, Mihalache C, Kozlowski E, et al. Viable neutrophils release mitochondrial DNA to form neutrophil extracellular traps. Cell Death Differ. 2009;16(11):1438-1444. doi: 10.1038/cdd.2009.96. Epub 2009 Jul 17.
  212. Youssenfian T, Drouin A, Massé JM, et al. Host defense role of platelets:engulfment of HIV and Staphylococcus aureus occurs in a specific subcellular compartment and is enhanced by platelet activation. Blood. 2002;99(11):4021-4029. doi: 10.1182/blood-2001-12-0191.
  213. You XJ, Bryant PJ, Jurnak F, Holcombe RF. Expression of Wnt pathway components frizzled and disheveled in colon cancer arising in patients with inflammatory bowel disease. Oncology Reports. 2007;18(3):691-694. doi: 10.3892/or.18.3.691.
  214. Yousefi S, Simon D, Simon HU. Eosinophil extracellular DNA traps: molecular mechanisms and potential roles in disease. Curr Opin Immunol. 2012;24(6):736-9. doi: 10.1016/j.coi.2012.08.010. Epub 2012 Sep 13.
  215. Vandijck DM, Blot SI, DeWaele JJ, et al. Thrombocytopenia and outcome in critically ill patients with blood stream infection. Heart Lung. 2010;39(1):21-26. doi: 10.1016/j.hrtlng.2009.07.005. Epub 2009 Oct 15.
  216. Varoga D, Pufe T, Harder J, et al. Human beta-defensin 3 mediates tissue remodeling processes in articular cartilage by increasing levels of metalloproteinases and reducing levels of their endogenous inhibitors. Arthritis Rheum. 2005;52(6):1736-1745. doi: 10.1002/art.21090.
  217. Varoga D, Pufe T, Mentlein R, et al. Expression and regulation of antimicrobial peptides in articular joints. Ann Anat. 2005;187(5-6):499-508. doi: 10.1016/j.aanat.2005.03.004.
  218. Varoga D, Pufe T, Harder J, et al. Production of endogenous antibiotics in articular cartilage. Arthrit Rheum. 2004;50(11):3526-3534. doi: 10.1002/art.20605.
  219. Venkataraman N, Cole AL, Svoboda P, et al. Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid. J Immunol. 2005;175(11):7560-7567. doi: 10.4049/jimmunol.175.11.7560.
  220. Vordenbaumen S, Timm D, Bleck E, et al. Altered serum levels of human neutrophil peptides (HNP) and human beta-defensin 2 (hBD2) in Wegener’s granulomatosis. Rheumatol Int. 2011;31(9):1251-1254. doi: 10.1007/s00296-010-1702-0. Epub 2010 Dec 4.
  221. Von Kockritz-Blickwede M, Nizet V. Innate immunity turne dinside-out:antimicrobial defense by phagocyte extracellular traps. J Mol Med. 2009;87(8):775-783. doi: 10.1007/s00109-009-0481-0. Epub 2009 May 16.
  222. Wafaisade A, Lefering R, Bouillon B, et al. Epidemiology and risk factors of sepsis after multiple trauma: an analysis of 29,829 patients from the Trauma Registry of the German Society for Trauma Surgery. Crit Care Med. 2011;39(4):621-8. doi: 10.1097/CCM.0b013e318206d3df.
  223. Wang CH, Chan LW, Johnson RN, et al. The transduction of Coxsackie and adenovirus receptor-negative cells and protection against neutralizing antibodies by HPMA-co-oligolysine copolymer-coated adenovirus. Biomaterials. 2011;32(35):9536-9545. doi: 10.1016/j.biomaterials.2011.08.069.
  224. Wang G. Human antimicrobial peptides and proteins. Pharmaceuticals. 2014;7(5):545-594. doi: 10.3390/ph7050545.
  225. Wang W, Cole AM, Hong T, et al. Retrocyclin, an antiretroviral thetadefensin, is a lectin. J Immunol. 2003;170(9):4708-4716. doi: 10.4049/jimmunol.170.9.4708.
  226. Wang W, Owen SM, Rudolph DL, et al. Activity of alpha- and theta-defensins against primary isolates of HIV-1. J Immunol. 2004;173(1):515-520. doi: 10.4049/jimmunol.173.1.515.
  227. Wang WM, Ye P, Qian Y-J, et al. Effects of whole cigarette smoke on human beta defensins expression and secretion by oral mucosal epithelial cells. Tob Induc Dis. 2015;13(1):3. doi: 10.1186/s12971-015-0029-8.
  228. Wiens ME, Jason G, Smith JG. Alpha-defensin HD5 inhibits furin cleavage of human papillomavirus 16 L2 to block infection. J Virology. 2015;89(5):2866-2874. doi: 10.1128/JVI.02901-14. Epub 2014 Dec 24.
  229. Wiethoff CM, Wodrich H, Gerace L, Nemerow GR. Adenovirus protein VI mediates membrane disruption following capsid disassembly. J Virol. 2005;79(4):1992-2000. doi: 10.1128/JVI.79.4.1992-2000.2005.
  230. Weissenhorn W, Hinz A, Gaudin Y. Virus membrane fusion. FEBS Lett. 2007;581(11):2150-2155. doi: 10.1016/j.febslet.2007.01.093.
  231. Wiesner J, Vilinskas A. Antimicrobial peptides. The ancient arm of the human immune system. Virulence. 2010;1(5):440-464. doi: 10.4161/viru.1.5.12983.
  232. Wimley WC, Selsted ME, White SH. Interactions between human defensins and lipid bilayers: evidence for formation of multimeric pores. Protein Sci. 1994;3(9):1362-1373. doi: 10.1002/pro.5560030902.
  233. Wehkamp WJ, Wang G, Kubler I, et al. The Paneth cell alpha-defensin deficiency of ileal Crohn’s disease is linked to Wnt/Tcf-4. J Immunol. 2007;179(5):3109-3118. doi: 10.4049/jimmunol.179.5.3109.
  234. Wehkamp J, Koslowski M, Wang G, Stange EF. Barrier due to distinct defensin deficiencies in small intestinal cjljnic Crohn’s disease. Mucosa Immunol. 2008;1(1):S67-S74.doi: 10.1038/mi.2008.48
  235. Wehkamp J, Fellermann K, Stange EF. Human defensins in Crohn’s disease. Chem Immunol Allergy. 2005;86:42-54. doi: 10.1159/000086672.
  236. Wehkamp J, Stange EF. Is there a role for defensins in IBD? Inflamm Bowel Dis. 2008;14(Suppl 2):S85-87. doi: 10.1002/ibd.20698.
  237. Wu Z, Cocchi F, Gentles D, et al. Human neutrophil alpha-defensin 4 inhibits HIV-1 infection in vitro. FEBS Lett. 2005;579(1):162-166. doi: 10.1016/j.febslet.2004.11.062.
  238. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448(7152):427-434. doi: 10.1038/nature06005.
  239. Zakynthinos SG, Papanikolaou S, Theodoridis T, et al. Sepsis severity is the major determinant of circulating thrombopoietin levels in septic patients. Crit Care Med. 2004;32(4):1004-1010. doi: 10.1097/01.CCM.0000121433.61546.A0.
  240. Zanetti M, Litteri L, Gennaro R, et al. Bactenecins, defense polypeptides of bovine neutrophils, are generated from precursor molecules stored in the large granules. J Cell Biol. 1990;111(4):1363-1371. doi: 10.1083/jcb.111.4.1363.
  241. Zapata W, Rodriguez B, Weber J, et al. Increased levels of human beta-defensins mRNA in sexually HIV-1 exposed but uninfected individuals. Curr HIV Res. 2008;6(6):531-538. doi: 10.2174/157016208786501463.
  242. Zawrotniak M, Rapala-Kozik M. D Neutrophil extracellular traps (NETs) - formation and implications. Acta Biochim Polonica. 2013;60(3):277-284.
  243. Zhang HH, Yang XM, Xie QM, et al. The potent adjuvant effects of chicken beta-defensin-1 when genetically fused with infectious bursal disease virus VP2 gene. Vet Immunol Immunophatol. 2010;136(1-2):92-97. doi: 10.1016/j.vetimm.2010.02.018. Epub 2010 Mar 4.
  244. Zhang L, Yu W, He T, et al. Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science. 2002;298(5595):995-1000. doi: 10.1126/science.1076185.
  245. Zhao L, Lu W. Defensins in innate immunity. Curr Opin Hematol. 2014;21(1):37-42. doi: 10.1097/MOH.0000000000000005.
  246. Zilbauer M, Jenke A, Wenzel G, et al. Intestinal alpha-defensin expression in pediatric inflammatory bowel disease. Inflammatory Bowel Diseases. 2011;17(10):2076-2086. doi: 10.1002/ibd.21577. Epub 2010 Dec 16.

Copyright (c) 2016 Vaschenko V.I., Vil’yaninov V.N., Shabanov P.D.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 65565 от 04.05.2016 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies